PD-1 inhibitor based immunotherapy

DRUG2 trials

Conditions

ChemoradiotherapyImmunotherapyNon-small Cell Lung CancerRectal AdenocarcinomaRectal CancerRectal Cancer PatientsRectal Cancer, RadiotherapyTargeted Therapy

Phase 2

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

RecruitingNCT07198165

Ruijin HospitalChemoradiotherapy, Immunotherapy, Rectal Adenocarcinoma +6

Start: 2025-09-05End: 2030-12-31Target: 104Updated: 2025-09-30

Unknown Phase

CX3CR1+T Cell Predict Immunotherapy Efficacy

CompletedNCT06054152

Shanghai Pulmonary Hospital, Shanghai, ChinaNon-small Cell Lung Cancer

Start: 2023-04-10End: 2025-06-20Updated: 2025-06-25

PD-1 inhibitor based immunotherapy

Sponsors

Conditions

Phase 2

Unknown Phase